DanCann Pharma A/S’ Board of Directors and Management have subscribed for units in the ongoing Rights Issue
COPENHAGEN, Denmark, 07 November 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that individuals in the Board of Directors and Management have subscribed for units in the ongoing Rights Issue.The Board of Directors decided on the 21 October 2022, with the authorization from the Extraordinary General Meeting that was held on the 20 September 2022, to conduct a Rights Issue of units of approx. 28.5 MDKK. The proceeds received from the Rights Issue will enable the Company to finalize its activities according